Drug Trial Radar · NCT04297995
Evaluate the Efficacy and Safety of HLX10 in Combination With HLX07 in Patients With Advanced Head and Neck Tumors
Last checked: Nov 19, 2026Latest source record: Aug 8, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
131
Planned (sponsor's estimate)
Start
Jul 29, 2020
Primary completion
May 30, 2024
Study completion Jun 30, 2025
Sponsor
- Lead sponsor
- Shanghai Henlius BiotechIndustry
- Sponsor type
- Industry
- First posted
- Mar 6, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Part1: A mutilpe-center, open-label, Phase II clinical trial to evaluate the efficacy and the safety of HLX10 in combination with HLX07 in patients with advanced advanced head and neck tumors. Part2: A randomized, double-blind, multi-center, phase II clinical study to evaluate the clinical efficacy and safety of HLX10 in combination with HLX07 and chemotherapy versus HLX10 in combination with placebo and chemotherapy in the first-line treatment of R/M HNSCC.
Conditions
- Head and Neck Squamous Cell Carcinoma
Interventions
HLX10Drug
Part 1: HLX10 3 mg/kg biweekly. Part 2: HLX10 300 mg every three weeks.
HLX07Drug
Part 1: HLX07 600 mg weekly (stage 1L). Part 1: HLX07 800 mg weekly (stage 1H). Part 2: HLX07 1000 mg every three weeks.
HLX07 placeboDrug
HLX07 placebo 1000 mg every three weeks
Cisplatin/CarboplatinDrug
Cisplatin 100 mg/m2 every three weeks. Cisplatin will be switched to carboplatin in case of intolerance to cisplatin. Up to 6 cycles.
5-FUDrug
5-FU 1000 mg/m2/day, 1-4 days, every three weeks. Up to 6 cycles.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part1: Efficacy-ORRTime frame: at 16 weeks after first dose
- Part1: Safety-adverse event profileTime frame: up to one year
- Part2: Efficacy-ORR (IRRC)Time frame: at 3 months after first dose
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Shanghai Henlius Biotech Inc.
Shanghai, Shanghai Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.